Tetracycline actions relevant to rosacea treatment

Skin Pharmacology and Physiology

Volumn 22, Issue 6, 2009, Pages 287-294

  Korting, H C ^a   Schollmann C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Cytokines; Doxycycline; Inflammation; Matrix metalloproteinases; Reactive oxygen species; Rosacea; Tetracyclines

Indexed keywords

AZELAIC ACID; DOXYCYCLINE; INTERLEUKIN 10; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METRONIDAZOLE; MINOCYCLINE; NITRIC OXIDE; PHOSPHOLIPASE A2; PLACEBO; REACTIVE OXYGEN METABOLITE; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ACNE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEMODEX; DEMODEX FOLLICULORUM; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; ERYTHEMA; EYE DISEASE; GRANULOMA; HUMAN; LOW DRUG DOSE; NONHUMAN; PERIODONTITIS; PRIORITY JOURNAL; REVIEW; ROSACEA; SKIN INFLAMMATION; TELANGIECTASIA; TREATMENT OUTCOME;

DOXYCYCLINE; HUMANS; INFLAMMATION; MITE INFESTATIONS; ROSACEA; TETRACYCLINES;

EID: 70349416933     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235550     Document Type: Review

References (88)

1. Blount BW, Pelletier AP: Rosacea: a common yet commonly overlooked condition. Am Fam Physician 2002; 66: 435-440, 442.
2. Berg M, Liden S: An epidemiological study of rosacea. Acta Derm Venereol 1989; 69: 419-423.
3. Kyriakis KP, Palamaras I, Terzoudi S, Emmanuelides S, Michailides C, Pagana G: Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005; 53: 918-919.
4. Eiseman AS: The ocular manifestations of atopic dermatitis and rosacea. Curr Allergy Asthma Rep 2006; 6: 292-298.
5. Dahl MV: Pathogenesis of rosacea. Adv Dermatol 2001; 17: 29-45.
6. Rebora A: The management of rosacea. Am J Clin Dermatol 2002; 3: 489-496.
7. Brinnel H, Friedel J, Caputa M, Cabanac M, Grosshans E: Rosacea: disturbed defense against brain overheating. Arch Dermatol Res 1989; 281: 66-72.
8. Yale SH, Vasudeva S, Mazza JJ, Rolak L, Arrowood J, Stichert S, Stratman ES: Disorders of flushing. Compr Ther 2005; 31: 59-71.
9. Pelle MT, Crawford GH, James WD: Rosacea. II. Therapy. J Am Acad Dermatol 2004; 51: 499-512.
10. Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ: Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-κB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol 2005; 166: 1691-1699.
11. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26.
12. Jones D: Reactive oxygen species and rosacea. Cutis 2004; 74(suppl 3):17-20, 32-34.
13. Bikowski J: Examining inflammation as a common factor in theories of rosacea pathophysiology. www.rosacea.org (last accessed November 24, 2008).
14. Oztas MO, Balk M, Ogüs E, Bozkurt M, Ogüs IH, Ozer N: The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28: 188-192.
15. Shanler SD, Ondo AL: Successful treatment of the erythema and flushing of rosacea using a topically applied selective α1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-1371.
16. Szlachic A: The link between Helicobacter pylori infection and rosacea. J Am Acad Dermatol Venereol 2002; 16: 328-333.
17. Bonnar A, Eusta P: The Demodex mite population in rosacea. J Am Acad Dermatol 1993; 28: 443-448.
18. Forton F, Seys B: Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993; 128: 650-659.
19. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E: A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 2008; 300: 125-131.
20. Hsu CK, Hsu MML, Lee JYY: Demodicosis: a clinicopathological study. J Am Acad Dermatol 2009; 60: 453-462.
21. Dhingra KK, Saroha V, Gupta P, Khurona N: Demodex -associated dermatologic conditions - a coincidence or an etiological correlate: review with a report of a rare case of sebaceous adenoma. Pathology Res Pract 2009; 205: 423-426.
22. Lacey N, Delaney S, Kavanagh K, Powell FC: Mite-related antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007; 157: 474-478.
23. Dolenc-Voljè M, Pohar M, Lunder T: Density of Demodex folliculorum in perioral dermatitis. Acta Derm Venereol 2005; 85: 211-215.
24. Schauber J, Ruzicka T, Rupec RA: Cathelicidin LL-37: ein zentraler Faktor in der Pathogenese entzündlicher Dermatosen? Hautarzt 2008; 59: 72-74.
25. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descarques P, Hoynanian A, Morhenn VB, Gallo RL: Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13: 975-980.
26. Schauber J, Gallo RL: Antimicrobial peptides and the skin immune defense system. Allergy Clin Immunol 2008; 122: 261-266.
27. Schmid-Wendtner MH, Korting HC: The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol 2006; 19: 296-302.
28. Korting HC, Schöllmann C: Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol 2009; 23: 876-882.
29. Thiboutot D, Thieroff-Ekerdt R, Graupe K: Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836-845.
30. Sapadin AN, Fleischmajer R: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-265.
31. Del Rosso JQ, Webster GF, Kackson M, Rendon M, Rich P, Torok H, Bradshaw M: Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56: 791-802.
32. Sneddon IB: A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649-652.
33. Baldwin HE: Systemic therapy of rosacea. Skin Therapy Lett 2007; 12: 1-5.
34. Del Rosso JQ: Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother 2004; 5: 5-13.
35. Bikowski JB, Goldman MP: Rosacea: where are we now? J Drugs Dermatol 2004; 3: 251-261.
36. Bikowski JB: Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003; 2: 234-245.
37. Thong YH, Ferrante A: Inhibition of mitogen- induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol 1979; 35: 443-446.
38. Sandler C, Nurmi K, Lindstedt KA, Sorsa T, Golub LM, Kovanen PT, Eklund KK: Chemically modified tetracyclines induce apoptosis in cultured mast cells. Int Immunopharmacol 2005; 5: 1611-1621.
39. Onoda T, Ono T, Dhar DK, Yamanoi A, Nasague N: Tetracyline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer 2006; 118: 1309-1315.
40. Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D'Amato R, Folkman J: Doxycycline induces membrane expression of VEcadherin on endothelial cells and prevents vascular permeability. FASEB J 2008; 22: 3728-3735.
41. Attur MG, Patel RN, Patel ND, Abramson SB, Amin AR: Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. J Immunol 1999; 162: 3160-3167.
42. Samuelsson B, Morgenstern R, Jakobsson PJ: Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007; 59: 207-224.
43. Maibach H: Second-generation tetracyclines, a dermatological overview: clinical uses and pharmacology. Cutis 1991; 48: 411-417.
44. Berman B, Perez OA, Zell D: Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barcelona) 2007; 43: 27-34.
45. Theobald K, Bradshaw M, Leyden J: Anti-inflammatory dose doxycycline (40 mg controlled- release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed 2007; 6: 221-226.
46. Walker C, Puumala S, Golub LM, Stoner JA, Reinhardt RA, Lee HM, Payne JB: Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results. J Periodontol 2007; 78: 1590-1601.
47. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, Casina A, Kapoor A, Zambon J, Ciancio S: Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. J Periodont Res 1984; 19: 651-655.
48. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991; 2: 297-322.
49. Webster G, Del Rosso JQ: Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25: 133-135.
50. Lalu MM, Cena J, Chowdhury R, Lam A, Schulz R: Matrix metalloproteinases contribute to endotoxin- and interleukin-1β-induced vascular dysfunction. Br J Pharmacol 2006; 149: 31-42.
51. Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR: The nonantimicrobial properties of tetracycline for the treatment of periodontal disease. Curr Opin Periodontal 1994; 2: 111-118.
52. Golub LM, Soumalainen K, Sorsa T: Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992; 2: 80-90.
53. Bonamigo RR, Bakos L, Edelweiss M, Cartell A: Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venereol 2005; 19: 646-647.
54. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC: Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 1999; 40: 2506-2512.
55. Uitto VJ, Firth JD, Nip L, Golub LM: Doxycyline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann NY Acad Sci 1994; 732: 140-151.
56. Choi DH, Moon IS, Choi BK, Paik JW, Kim YS, Choi SH, Kim CK: Effects of sub-antimicrobial dose doxycycline on crevicular fluid MMP-8, and gingival tissue MMP-9, TIMP-1 and IL-6 levels in chronic periodontitis. J Periodont Res 2004; 39: 20-26.
57. Reddy MS, Geurs NC, Gunsolly JC: Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents: a systematic review. Ann Periodontol 2003; 8: 12-37.
58. Buduneli E, Vardar-Sengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T: Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase- 1, and laminin-5 γ2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and aledronate. J Periodontol 2007; 78: 127-134.
59. Ciancio S, Ashley R: Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998; 12: 27-31.
60. Golub LM, Lee HM, Stoner JA, Porsa T, Reinhardt RA, Wolff MS, Ryan ME, Nummikoski PV, Payne JB: Subantimicrobialdose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol 2008; 79: 1409-1418.
61. De Paiva CS, Corrales RM, Villareal AL, Farley WJ, Li DQ, Stern ME, Pflugfelder SC: Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006; 83: 526-535.
62. Kim HS, Luo L, Pflugfelder SC, Li DQ: Doxycycline inhibits TGF-β-induced MMP-9 via SMAD and MAPK pathways in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2005; 46: 840-848.
63. Määtä M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, Sorsa T: Tear fluid levels of MMP-8 are elevated in ocular rosacea - treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 2006; 244: 957-962.
64. Corbitt CA, Lin J, Lindsey ML: Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat Anticancer Drug Discov 2007; 2: 135-145.
65. Smith VA, Khan-Lim D, Anderson L, Cook SD, Dick AD: Does orally administered doxycycline reach the tear film? Br J Ophthalmol 2008; 92: 856-859.
66. Pruzanski W, Greenwald RA, Street IO, Laliberte F, Stefanski E, Vadas P: Inhibition of enzymatic activity of phospholipase A2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44: 1165-1170.
67. Mäkelä A, Kuusi T, Schröder T: Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997; 57: 401-407.
68. Kari O, Aho VV, Peltonen S, Kari M, Määtä M, Collan Y, Saari KM: Group IIA phospholipase A 2 concentration of tears in patients with ocular rosacea. Acta Ophthalmol Scand 2005; 83: 483-486.
69. Del Rosso JQ: A status report on the medical management of rosacea: focus on topical therapies. Cutis 2002; 70: 271-275.
70. Cazalis J, Bodet C, Gagnon G, Grenier D: Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models. J Periodontol 2008; 79: 1762-1768.
71. Chung DR, Lee YS, Lee SS: Kinetics of inflammatory cytokines in patients with scrub typhus receiving doxycycline treatment. J Infect 2008; 56: 44-50.
72. Gürkan A, Cinarcik S, Hüseyinov A: Adjunctive subantimicrobial dose doxycycline: effect of clinical parameters and gingival crevicular fluid transforming growth factor-β levels in severe, generalized chronic periodontitis. J Clin Periodontol 2005; 32: 244-253.
73. Esterly NB, Koransky JS, Furey NL, Trevisan M: Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984; 120: 1308-1313.
74. Gabler WL: Fluxes and accumulation of tetracyclines by human blood cells. Res Commun Chem Pathol Pharmacol 1991; 72: 39-51.
75. Gabler WL, Creamer HR: Suppression of human neutrophil functions by tetracyclines. J Periodont Res 1991; 26: 52-58.
76. Gabler WL, Tsukuda N: The influence of divalent cations and doxycycline on iodoacetamide- inhibitable leukocyte adherence. Res Commun Chem Pathol Pharmacol 1991; 74: 131-140.
77. Webster GF, Toso SM, Hegemann L: Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin: involvement of protein kinase C. Arch Dermatol 1994; 130: 748-752.
78. Bakar O, Demircay Z, Yuksel M, Haklar G, Sanisoglu Y: The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 2007; 32: 197-200.
79. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P: Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997; 43: 1209-1214.
80. Tisma VS, Basta-Juzbasic A, Jaganjac M, Brcic L, Dobric I, Lipozencic J, Tatzber F, Zarkovic N, Poljak-Blazi M: Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol 2009; 60: 270-276.
81. Miyachi Y, Yoshioka A, Imamura S, Niwa Y: Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986; 86: 449-453.
82. Akamatsu H, Asada M, Komura J, Asada Y, Nowa Y: Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol 1992; 72: 178-179.
83. Amin AR, Attur MG, Thakker GD, Patel PD, Yvas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: Proc Natl Acad Sci USA 1996; 93: 13014-13019.
84. Roméro-Graillet C, Aberdam E, Clément M, Ortonne JP, Ballotti R: Nitric oxide produced by ultraviolet-irradiated keratinocytes stimulates melanogenesis. J Clin Invest 1997; 99: 635-642.
85. Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB: Posttranscriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett 1997; 410: 259-264.
86. Gomaa AH, Yaar M, Eyada MM, Bhawan J: Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 2007; 34: 748-753.
87. Lee CZ, Xu B, McCulloch CE, Yang GY, Young WL: Doxycyline suppresses cerebral matrix metalloproteinase-9 and angiogensis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35: 1715-1719.
88. Yao JS, Shen F, Young WL, Yang GY: Comparison of doxycyline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int 2007; 590: 524-530.